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S_m.ary Over 27000 patients with breast cancer were identified from cancer registry data from 1978 to
1992 and differences in treatment practice across the 16 districts of Yorkshire studied. A total of 50 surgeons
treated more than an average of ten cases a year. Surgeons who expressed an interest in breast cancer were
more likely to treat a greater number of patients than those who had no special interest in the disease and
offered patients chemotherapy, hormone therapy and radiotherapy more often. The average regional mastec-
tomy rate fell from 70% to 44% over this period, but the rate varied between districts from 13% to 87%, with
those at the extremes occupying these positions year on year. The rate of uptake of radiotherapy varied
between districts from 13% to 58% over the period 1978-92. The use of adjuvant chemotherapy increased
from 5% to 19% and hormone therapy from 19% to 80% over this time period. An audit of the facilities
available within each district carried out in early 1994 also showed considerable variation, although all districts
now have access to a nurse specialist. There were wide variations in treatment offered to patients with breast
cancer. Patients in some districts were denied access to chemo- and radiotherapy despite published guidelines
showing these modalities to be useful. It is recommended that patients are referred to units with an interest in
breast cancer rather than to general surgical out-patients.
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It has been known for some time that there is a wide
variation in take-up of treatment options for patients with
breast cancer across the country and there are perceptions
(undocumented) that some centres offer 'better' treatments
than others. It is not clear if this translates into a survival
advantage. The management of rarer cancers such as germ
cell tumours and childhood leukaemia requiring intensive
treatments have been concentrated in specialist centres with
improvements in survival rates (McCarthy, 1975; Stiller,
1988).
The Yorkshire Breast Cancer Group (YBCG) was estab-
lished 20 years ago by a group of surgeons with an interest in
the disease and initially collected data on prognostic factors.
It has sponsored trials into conservation therapy and has
generally increased interest in management of the disease
across Yorkshire. Not all surgeons treating breast cancer are
members.
This paper examines firstly the treatment patterns of
patients with breast cancer across Yorkshire related to dist-
rict of residence, surgeon (whether or not they are members
of the YBCG) and radiotherapist for the years 1978-92 and,
secondly, a prospective audit of facilities available in each
district. There are constraints to a study such as this - only
treatments within 9 weeks of diagnosis were recorded. Most
districts did not have access to a medical oncologist at this
time.
Patiets and methods
Cancer registry data for the years 1978-92 were used. The
cancer registry recorded 70 data items for each patient record
during this period. These included extent ofdisease at presen-
tation, consultants and hospitals of management during the
initial 9 week treatment period, treatment modalities used
and date and cause of death. The use of radiotherapy was
recorded, as was the use of chemotherapy and hormone
therapy. Surgical procedure codes were grouped as mastec-
tomy or lumpectomy (the latter included partial mastectomy)
for the purposes of this study, and only the first two opera-
tions undergone by each patient were included in the
analysis. Patients receiving lumpectomy followed by mastec-
tomy during the initial treatment period were categorised as
receiving the latter only. All cases of primary breast cancer
diagnosed by cytology or histology were included, including
multiple primary breast tumours. Concerns over com-
pleteness of data collection were addressed and a cross-check
was, therefore, made with one district where all cases had
been prospectively registered on a separate system. Only
treatments starting within 9 weeks of the date of first
definitive treatment were included.
As part of the cancer registry each district has its own
clerk who is responsible for checking the notes and extracting
data, although the initial registration routinely comes from
the pathology laboratory. Disease stage was poorly recorded
in the earlier years and is not included in this analysis.
The percentage of registrations by death certificate only
(DCO) and the percentage of cases histologically confirmed
was audited as an indicator of quality of the data. Analysis
was undertaken by district of residence regardless of where
the patient was treated. The name of the surgeon to whom
the patient was referred and who carried out treatment was
identified and coded, as was the radiotherapist involved.
Each district is served by a radiotherapist who is based either
at the regional centre in Cookridge Hospital, Leeds, or in the
subregional centre at Hull. Some patients, therefore, have a
considerable distance to travel for treatment. Radiotherapy
rates quoted were for patients actually treated and not for
those referred for an opinion as to, say, adjuvant
chemotherapy.
The prospective audit of facilities available was carried out
by telephone conversation with surgeons, radiologists, breast
nurses and managers in each district. Discrepancies between
perceived and actual services were resolved by cross-checking
through other sources. These included breast nurses, ward
and theatre staff and local managers.
Statistical methods employed included Kaplan-Meier life
table analysis and K sample log-rank test.
The recently described probability of recurrence of extreme
data method (Palmer, 1993) was used for analysis of the rates
of lumpectomy, radiotherapy and mastectomy. Districts were
ranked on a percentage basis and the number of times they
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ranked first (or last) summated. As the number of districts
and time observations were known, an estimate of the chance
of a district providing care that lay at one extreme could be
made.
A 4 x 4 grid was constructed for each district to enable a
visual comparison to be made of the percentage of patients
having surgery, radiotherapy, chemotherapy and hormone
treatment, either separately or in combination (see Figure 6).
Results
Only 625 of the 27 216 registrations between 1978 and 1992
were DCOs (2.3%). In 84.2% (22 903 cases) the disease was
confirmed histologically (Table I). The cross-check between
cancer registry data and those held on a stand-alone system
in one district revealed 113 out of 116 invasive cancers to be
correctly registered for 1991 (97.4%). The age-standardised
incidence of breast cancer in Yorkshire was 103 per 100 000
(1981-92), with one district having 80-90% this rate and
one between 110% and 120%. The overall 10 year survival
for patients with breast cancer in Yorkshire was 37% with a
median survival of 6.4 years (10 year relative survival of
51.3%).
The regional age-standardised mortality was 47.38 per
100 000 (1981-92). which was 90% compared with the
national average for this period. One distnrct had consistently
better mortality rates (80-90% of the regional average),
three between 110% and 120% and one > 120% of this
figure (P<0.01).
The regional mastectomy rate is shown in Figure 1. There
were wide variations between districts with a mastectomy
rate ranging from 13% to 87%. When districts were ranked
for percentage of cases treated by mastectomy there was
significant variation (P<0.0001; Palmer's method) sugges-
ting that some persistently carried out more mastectomies
than others. The gradual adoption of conservation therapy
(lumpectomy ± radiotherapy) can be seen in Figure 2. Again
there are significant differences between distnrcts (P = 0.037;
Palmer's method). Cross-examination of a sample of cancer
registry treatment data with clinical trials data for the period
1981-86 indicated a shortfall of less than 2% in the recor-
ding of both surgical procedures and radiotherapy treatments
(unpublished).
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Figre 1 Mastectomy rates for 1978-92. Vertical bars indicate
percentage range between districts across their region. The district
with the average highest rate is shown as the square box and
occupies this position year on year (P<0.001. this district vs
regional average).
The percentage of patients receiving radiotherapy showed
wide variations (Figure 3). One district averaged 13%
patients treated by this modality over the last 15 years
(1978-92), while another averaged 58%. If the last 5 years
(1988-92) are taken, the rates have narrowed to between
20% and 59% for these two districts but they still differ
significantly from the regional mean (P<0.001). This varia-
tion was not accounted for solely by increasing use of
lumpectomy as conservation therapy - in some districts
patients were routinely receiving radiotherapy after mastec-
tomy.
The trend for treatments that include hormonal manipula-
tion and adjuvant chemotherapy is shown in Figure 4.
The number of patients managed by each surgeon varied
widely. In only one district did all the breast work go to an
individual. Twenty-one YBCG surgeons treated 51% of the
cases, while 84 non-YBCG surgeons treated 49% of the
patients over the years 1983-92. Fifty-one non-YBCG
surgeons treated fewer than 99 cases in the decade, whereas
all YBCG surgeons saw more than these numbers (Figure 5).
Patients seen by a YBCG surgeon were less likely to receive a
mastectomy. Allowance was made for retirement and
appointment of individuals. An example of the differences in
treatment modalities used in each distnrct is shown in Figure
6. The prospective enquiry into facilities available across the
region showed (Table II) few centres yet offering a complete
service and only two offering a same day diagnostic service.
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F%gure 2 Lumpectomy rates by district (1978-92) showing in-
creasing adoption of lumpectomy as a therapautic option. The
vertical bars represent the range between districts across the
region. The districts with the highest and lowest percentage use of
lumpectomy are indicated by an asterisk or triangle and are seen
to occupy this position from year to year until 1992 (P = 0.037,
these outliers vs the regional average).
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FVgre 3 Radiotherapy uptake for 1978-92. The district with
the lowest uptake is shown by a triangle. P<0.001 for this
district vs regional average (or any other district).
Table I Data quality: percentage of death certificate (DCO) and histologically confirmed
registrations of breast cancer. 1978-92. Those cases without histological confirmation were
diagnosed on clinical grounds (including mammography)
No. of (%0 histologically
Years No. ofregistrations No. of (0%0 DCOs confirmed cases
1978-82 8353 165 (2.0) 6902 (82.6)
1983-87 8830 234 (2.7) 7189 (81.4)
1988-92 10033 226 (2.3) 8812 (87.8)
1978 -92 27216 625 (2.3) 22903 (84.2)
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Figre 4 Adoption of hormone or chemotherapy from 1978 to
1992. Figures are percentages of patients treated.
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Figue 5 Surgical workload for YBCG (0) and non-YBCG (U)
surgeons. The vertical axis refers to the number of surgeons
active at that time and the number of cases treated is given below
each set of bars. Adjustment is made for new arrivals and
retirements.
Table II Facilities available across Yorkshire (1994)
Dedicated breast clinic 11
Breast nurse nurse counsellor 16
Fine-needle cytology used regularly 8
Mammography at first visit 6
Ultrasound available in clinic or on request 3
Districts contributing to NHS BSP0 16
Surgical units administering chemotherapy 6
Identified breast ward or breast beds 2
Reconstruction available in district 5
Entering patients into studies 6
n= 16; NHS BSP. NHS Breast Screening Programme. "Managing
patients diagnosed by the screening programme assessment centres.
Dbuson
This study is based on cancer registry data and is, therefore,
representative of initial treatment received. It thus differs
from previous studies of variation that have been based on
questionnaires (Gazet et al., 1985; Morris et al.. 1989; Mor-
ris, 1992), which may be open to bias as reply rates of only
around 60% are common.
Within Yorkshire's 16 districts different facilities were
available for the investigation and treatment of breast cancer
(Table I). Only one district had all the facilities listed and
three had only three of the listed criteria. The number of
patient visits to achieve a diagnosis varied widely (from 1 to
4). This was dependent, to some extent, on the facilities
available locally. Units with a dedicated breast unit were
more likely to achieve an early diagnosis than those where
patients had to reattend for each investigation. With a
dedicated breast unit the majority of cases of symptomatic
breast cancer should be diagnosable at first visit.
The treatments offered varied widely, with significantly
higher levels of mastectomy in some districts. This is similar
to the findings of a postal survey that showed geographic
variations in the likelihood of a patient receiving a mastec-
tomy (Morris, 1992). Adjuvant chemotherapy is increasingly
DintrimI B n-776
Ra-dthapvCM)}
I_ k.i'mum
0 0 10
ma a(42 u
Figure 6 Example of different treatment profiles for two districts
over the period 1988-92. Columns I and 2 represent percentage
uptake of radiotherapy and rows 1 and 2 of surgery. Hence in
district A 3% of patients had surgery, radiotherapy and
chemotherapy (columns 2 and 3). whereas 23% of patients were
treated this way in district B. Column 4 represents no radio- or
chemotherapy and row 4 represents no surgery or hormone
therapy. This allows a companrson of treatments administered in
each district over a given time peniod. Its use as an annual
statement of treatment facilitates audit. Figures are in percen-
tages and are shaded. Clear boxes represent no patients receiving
this treatment. Light shading represents 1-9% having such a
treatment, moderate shading represents between 10 and 24% and
darker shading more than 25%.
being offered, but indications for its use and regimen used
vary greatly; within the Yorkshire region there were at least
six different CMF regimens in use, and one centre has until
recently given thio-tepa as an adjunctive therapy. During the
decade studied there were still surgeons who saw few cases of
breast cancer (55 treated fewer than an average ten cases a
year). Whether workload has an effect on relapse rates and
survival cannot be extrapolated from these data but does
appear to influence standardisation of treatments.
Variation of treatments may per se be legitimate when
there is significant uncertainty as to what is best but may
indicate failure to use best current practice. Despite the
King's Fund Consensus statement on the best management
of early breast cancer (Anon, 1986) and the Standing
Medical Advisory Committees' (1991) report on ovarian
cancer there is little evidence of a major change in practice at
local level. The overview of chemotherapy for patients with
early breast cancer (Early Breast Cancer Triallists Col-Tr_eat wa--W fv rec rnYuksive x R Snsbuty et a
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laborative Group 1992) clearly showed that premenopausal
patients with node-positive disease benefited from such treat-
ment but these lessons are only now beginning to be add-
ressed by some. This may be because of organisational prob-
lems with unwillingness to provide such services or may be
secondary to clinicians' individual perceptions of the
cost-benefit ratio for chemotherapy. Farrow et al. (1992)
have shown geographical variation in the treatment of 'early'
breast cancer in the United States, and a study from Illinois
has shown that small urban hospitals are likely not to pro-
vide comprehensive diagnosis and treatment (Hand et al.,
1991). In our study we could find no difference between
teaching and non-teaching districts when they were analysed
for rates of mastectomy or radiotherapy uptake.
A recent report from Japan (Izuo & Ishada, 1994) has
shown similar variations in treatment, with a rural/urban
divide being evident.
One area of breast cancer treatment on which there are
clear recommendations is the treatment of screen-detected
lesions. NHS Breast Screening Quality Assurance guidelines
state that patients with screen-detected lesions should be
treated by one or two designated surgeons in each screening
cluster. This is not yet the case, and as for patients with
symptoms, patients detected by screening are dealt with by
more than one or two surgeons in some districts. This may
well be putting patients at a disadvantage as the chance of
completeness of excision of impalpable disease is dependent
on surgical expertise (JM Dixon, personal communication).
Tlhe variation in rate of mastectomy is large and of con-
cern. Districts at either end of the range occupied that posi-
tion year on year, and it would seem that this was because of
surgical philosophy rather than disease stage. In the district
with the persistently highest rate of mastectomies, all
surgeons carried out breast work and, although one surgeon
was a YBCG member, his numbers were thus diluted. There
was no correlation between availability of radiotherapy and
mastectomy rate. The lumpectomy rate showed an overall
increase over the decade, but again it was used as a treatment
option more in some centres than in others. The general
increase in lumpectomy as a treatment option had a 'knock
on' effect for radiotherapy services. Why the use of
radiotherapy varied so greatly between districts is interesting.
It does not appear to be a reflection of the type of surgery
performed, as the district with a low uptake of radiotherapy
also has a lower than average mastectomy rate. This can be
seen in the 4 x 4 tables constructed for each district (Figure
6). It might be that surgeons within this district were sur-
gially 'aggressive', performing repeated excisions before
referral for radiotherapy, thus resulting in the referral falling
outside the 9 week period from initial treatment episode
required for registration purposes (or not referring their
patients at all). There were no data on failure of local
controL which makes it difficult to determine if this policy
was acceptable. The time cut-off may also account to some
extent for the apparently low uptake of adjuvant
chemotherapy - in the past radiotherapy was given first with
chemotherapy starting later, whereas now chemotherapy is
increasingly given earlier, with radiotherapy being delayed or
fitted in. The waiting time for radiotherapy for patients with
breast cancer at one point rose to an unacceptably long time
of 12-13 weeks, but this has been addressed recently and has
been reduced to 6 weeks on average for the west of the
county by extending the daily use of the linear accelerators.
While the data on treatments received were 2 years out of
date and thus might not be representative of the current
situation, those relating to the facilities available were
obtained prospectively. It is pleasing that all districts now
have a dedicated breast nurse specialist/counsellor, yet even
in 1994 only 11 ran a dedicated breast clinic. Eight had
access to cytology reports within 24 h, but only six districts
were able to arrange for mammography at the first clinic
visit. Six surgical teams administered adjuvant chemotherapy
to their own patients, while in three others the patient
travelled to another hospital. It was not clear whether pro-
tocols for administration of this chemotherapy had been
agreed with a medical oncologist or a radiation (clinical)
oncologist. This area has now been addressed, and protocols
are now used after discussion with an oncologist.
Two districts had a dedicated breast ward or identified
breast beds within a general ward. Five districts carried out
their own breast reconstruction, although only one offered
flaps. It was disappointing to see that only six districts were
entering patients into clinical studies, although this is chang-
ing as the Yorkshire-based study on intervention and timing
of surgery gets under way.
Information about the quality of local services will be
increasingly important in the future as contracts of provision
of services are made. It is clear that a degree of specialisation
needs to occur, with breast work going to one or two
surgeons in each district, but a decision also needs to be
made as to whether the patient is best served by each district
providing a comprehensive range of services or whether sub-
regional groupings should occur. Diagnostic clinics might,
perhaps, be based in each district with in-patient care being
based in one centre. The majority of breast work is out-
patient, and if high standard breast cinics were developed
the number of in-patient episodes could be reduced. We
found that some districts are still admitting patients for
diagnostic biopsies as fine-needle cytology was not used and
others were admitting patients for staging investigations such
as bone scans despite clear evidence that they serve no useful
purpose in patients with stage I disease.
Guidelines for the management of symptomatic breast
disease are in preparation by a number of groups and should
allow a fuller debate about the placement and extent of
breast services. These have been drawn up by the British
Association for Surgical Oncology and the British Breast
Group and are currently out for discussion. It is likely that
purchasers of health care will require evidence of practice
according to such guidelines in placing contracts for this
work.
Treatment for patients with breast cancer did vary
significantly according to residential district, with suboptimal
therapy being administered in some districts in the past.
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